Preclinical And Clinical Development Of Oncolytic Adenovirus For The Treatment Of Malignant Glioma.

ABSTRACT: Replication conditional oncolytic human adenovirus has long been considered a promising biological therapeutic to target high-grade gliomas (HGG), a group of essentially lethal primary brain cancer. The last decade has witnessed initiation and some completion of a number of Phase I and II clinical investigations of oncolytic adenovirus for HGG in the US and Europe. Results of these trials in patients are pivotal for not only federal approval but also filling an existing knowledge gap that primarily derives from the stark differences in permissivity to human adenovirus between humans and preclinical mouse models. DNX-2401 (Delta-24-RGD), the current mainstream oncolytic adenovirus with modifications in E1A and the fiber, has been shown to induce impressive objective response and long-term s

SUBMITTER: Kiyokawa J 

PROVIDER: S-EPMC6817710 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature